Yes, but you should carry a copy of the prescription and a letter from your prescriber describing the medical necessity. Some countries require documentation for benzodiazepine-type substances at border control.
In markets where it is sold, the 50 mg tablet often bears a numeric code such as “50 TOF” or a manufacturer’s logo. Verify the imprint against the pharmacy label before use.
Standard workplace or sports drug screens typically target classical benzodiazepines (e.g., diazepam, lorazepam). Tofisopam may not be included in routine panels, but specialised testing can detect it.
Tofisopam provides anxiolysis with minimal sedation, muscle relaxation, or anticonvulsant activity, whereas classic benzodiazepines exhibit all of these effects. This difference stems from its distinct binding profile at the GABA-A receptor.
Co-administration is generally permissible, but both drugs influence serotonin pathways and CNS activity. Monitoring for increased anxiety or sedation is advisable.
Take the missed dose as soon as you remember, unless it is close to the time of your next scheduled dose. In that case, skip the missed dose and resume your regular schedule-do not double-dose.
There is no specific evidence linking tofisopam to intra-ocular pressure changes. However, patients with narrow-angle glaucoma should discuss any new CNS-active medication with an ophthalmologist.
The MHRA has not granted a marketing authorisation for tofisopam in the UK, largely because alternative anxiolytics with established safety profiles are already available.
Yes, the medication is sold as a generic 50 mg tablet without a brand label in countries where it is approved.
The tablet is formulated for whole-tablet ingestion. Splitting or crushing may alter absorption and should only be done if explicitly advised by a pharmacist.
Tofisopam is a benzodiazepine-derived anxiolytic available as a generic medication. It is marketed in some countries under various brand names, but in the United Kingdom it is not currently listed on the NHS formulary. The active ingredient is tofisopam itself. It is supplied as a 50 mg pill for oral use.
Tofisopam belongs to the 1,4-benzodiazepine family. Unlike classic benzodiazepines, it produces anxiety relief with minimal sedation, muscle relaxation, or anticonvulsant effects.
In regions where it is approved, tofisopam is indicated for the short-term treatment of anxiety disorders and adjustment disorder with anxious mood. It may be used when a non-sedating anxiolytic is preferred.
Regulatory note (UK): To date, the Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a marketing authorisation for tofisopam in the United Kingdom. Patients should only use the medication when prescribed by a qualified prescriber outside the UK and imported in accordance with local law.
If you fall into any of these categories, discuss alternative therapies with your healthcare provider.
If you are taking other prescription or over-the-counter products, inform your prescriber to evaluate possible interactions.
This article provides educational information about tofisopam and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
